Research and Innovation

New CAR T-cell therapy for leukaemia associated with less dangerous side effects

A clinical trial to investigate a novel CAR T-cell therapy, designed to target cancer cells more quickly and cause less side effects, has shown very promising results for children with previously incurable acute lymphoblastic leukaemia (ALL). 

European clinical trial for Kawasaki disease to be led by GOSH and ICH researchers

Researchers at the UCL Great Ormond Street Institute of Child Health (ICH) and Great Ormond Street Hospital (GOSH) are to lead a new clinical trial for Kawasaki syndrome (KD-CAAP), a rare immune system condition that causes swelling of the blood vessels of the heart and can lead to severe fever and risk of heart problems such as aneurysms.

Gene therapy treatment manufactured at GOSH and ICH used to treat world's first patient with life limiting genetic condition, MPSIIIA

A two-year old patient at the Royal Manchester Children’s Hospital (RMCH) is the first in the world to receive a pioneering new gene therapy treatment for the rare and life-limiting genetic condition, Mucopolysaccharidosis IIIA (MPSIIIA). The treatment was manufactured at Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (ICH) after being developed by RMCH and the University of Manchester.

Pages